Cytovir ADV is a personalized cellular immunotherapy consisting of donor-derived (allogeneic), naturally-occurring, expanded ADV (adenovirus)-specific T cells. This investigational medicinal product is currently under early clinical development for the treatment of ADV infections following an allogeneic hematopoietic stem cell transplantation (allo-HSCT).
We manufacture Cytovir ADV from a donor whole blood collection or aliquot of stem cell graft, using our OneTouch manufacturing process.
We are currently evaluating the safety and efficacy of Cytovir ADV for the treatment of ADV infections following a HSCT in pediatric patients in the ASPIRE clinical trial. Cytovir ADV is available in the UK upon request of a qualified physician under the ‘specials’ legislation.
Cell Medica has sponsored a clinical trial (ASPIRE) assessing the safety and efficacy of of Cytovir ADV in pediatric patients with an ADV reactivation after an allogeneic stem cell transplant. This trial is now complete.